National Healthcare Agreement: PB c–Better health: reduce the age-adjusted prevalence rate for Type 2 diabetes to 2000 levels (equivalent to a national prevalence rate (for 25 years and over) of 7.1 per cent) by 2023, 2022

Collection and usage attributes

25 years

Proxy measure:

The National Health Measures Survey (NHMS) component of the 2011–13 Australian Health Survey included a fasting plasma glucose test. Participation in the NHMS component was voluntary.

A respondent to the survey is considered to have known diabetes if they had ever been told by a doctor or nurse that they have Type 2 diabetes and:

• they were taking diabetes medication (either insulin or tablets); or
• their blood test result for fasting plasma glucose was greater than or equal to 7.0 mmol/L).

A respondent to the survey is considered to have newly diagnosed diabetes if they reported no prior diagnosis of diabetes, but had a fasting plasma glucose value greater than or equal to 7.0 mmol/L.

Excludes persons who did not fast for 8 hours or more prior to their blood test.

Excludes women with gestational diabetes.

Rates are directly age-standardised to the 2001 Australian population.

Analysis by remoteness and Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socio-Economic Disadvantage (IRSD) is based on usual residence of person (subject to data availability).

Presented as a percentage.

95% confidence intervals and relative standard errors are calculated for rates.

Note: The type of diabetes for newly diagnosed cases cannot be determined from a fasting plasma glucose test alone.  However, it is assumed that the vast majority of newly diagnosed cases would be Type 2.

Crude rate: 100 x (numerator/denominator)

Number of persons aged 25 and over with known diabetes (Type 2) or newly diagnosed diabetes as determined by a fasting plasma glucose test.

Population aged 25 and over.

State and territory, by:

• sex
• Indigenous status (non-Indigenous only).

Nationally, by:

• remoteness (Australian Statistical Geography Standard (ASGS 2011) Remoteness Structure)
• 2011 SEIFA IRSD quintiles.

State and territory by Indigenous status (Indigenous only).

Some disaggregations may result in numbers too small for publication.

Most recent data available for 2022 National Healthcare Agreement performance reporting: 2011–12 (total population, non-Indigenous: AHS); 2012–13 (Indigenous only: AATSIHS).

NO NEW DATA FOR 2022 REPORTING.

The baseline measure of 7.1% is calculated from the Australian Diabetes, Obesity and Lifestyle Studyconducted in 1999–2000. Note that this number was age-standardised to the average of the 1999 and 2000 Australian populations, and was based on data from both oral glucose tolerance tests (OGTTs) and fasting plasma glucose tests. As an OGTT was not conducted as part of the National Health Measures Survey, the data supplied for the 2014 COAG Reform Council report are not comparable to the baseline measure of 7.1%.

Fasting plasma glucose test data will be supplied as a proxy from the AHS for this benchmark, age-standardised to the 2001 Australian population.  The equivalent baseline measure from the Australian Diabetes, Obesity and Lifestyle Study, age-standardised to the 2001 Australian population and using fasting plasma glucose test data, has been calculated to be a rate of 5.0%.

Further details on the prevalence of Type 2 diabetes among Indigenous Australians are available from the Aboriginal and Torres Strait Islander Health Performance Framework (measure 1.09: Diabetes and measure 3.05: Chronic disease management).

Representational attributes

N[NN].N

Indicator conceptual framework

Data source attributes

Accountability attributes

National Healthcare Agreement

Australian Bureau of Statistics

National Healthcare Agreement Performance Benchmark:

Reduce the age-adjusted prevalence rate for Type 2 diabetes to 2000 levels (equivalent to a national prevalence rate (for 25 years and over) of 7.1%) by 2023.

Refer National Healthcare Agreement 2012.

Specification: Final, the measure meets the intention of the indicator.

Source and reference attributes

Australian Bureau of Statistics (ABS) (Reference period: 2011–12). Australian Health Survey: Biomedical Results for Chronic Diseases. ABS Website. Viewed 19 February 2021, https://www.abs.gov.au/statistics/health/health-conditions-and-risks/australian-health-survey-biomedical-results-chronic-diseases/latest-release

Australian Institute of Health and Welfare (AIHW) 2020. Aboriginal and Torres Strait Islander Health Performance Framework. Canberra: AIHW. Viewed 19 February 2021, https://indigenoushpf.gov.au/

Baker Heart & Diabetes Institute n.d. About AusDiab. Melbourne: Baker Heart & Diabetes Institute. Viewed 11 May 2020, https://www.baker.edu.au/ausdiab/

Council of Australian Governments 2012. National Healthcare Agreement (effective 25 July 2012). Viewed 5 May 2020, http://www.federalfinancialrelations.gov.au/content/npa/health/
_archive/healthcare_national-agreement.pdf

Relational attributes